title: Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
abstract: This study evaluated the efficacy and tolerability in the initiation treatment of Concerta (OROS methylphenidate HCl) in Korean children with Attention-Deficit/Hyperactivity Disorder (AD/HD). One hundred and nineteen children with AD/HD were entered into a multi-center, open-label, four-week trial. The dosage of Concerta was adjusted by the investigators based on symptoms and safety assessments performed on a weekly basis. The safety of the drug and its efficacy for attention, behavior, and cognitive function were assessed. The primary outcome measures for efficacy were the Parent and Teacher IOWA Conners Rating Scales, Peer Interaction Items, and the Clinical Global Impression Scale. Cognitive tests (Continuous Performance Test, Matched Familiar Figure Test, Verbal Fluency Test, and Trail Making Test) were included as the secondary outcome measures. In most participants, OROS methylphenidate was well tolerated. There were significant improvements in attention, behavior, and function as measured by parents, teachers, and investigators. The benefit of the initiation of OROS methylphenidate in children with AD/HD was shown on the cognitive tests as well. These data provide support for the benefit of the once-daily methylphenidate preparation, Concerta in the treatment of Korean children with AD/HD. Children were initiated safely in this short-term trial, and its effectiveness was evident in the behavioral, as well as neuropsychological measurements.
authors.affiliation: Department of Psychiatry, Soonchunhyang University Bucheon Hospital, College of Medicine, Soonchunhyang University, South Korea.
authors.forename: Soyoung Irene
authors.initials: SI
authors.lastname: Lee
authors.forename: Sungdo David
authors.initials: SD
authors.lastname: Hong
authors.forename: Sang-Yeup
authors.initials: SY
authors.lastname: Kim
authors.forename: Eui-Jung
authors.initials: EJ
authors.lastname: Kim
authors.forename: Ji-Hae
authors.initials: JH
authors.lastname: Kim
authors.forename: Ji-Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Mi-Kyoung
authors.initials: MK
authors.lastname: Park
authors.forename: Sehyeon
authors.initials: S
authors.lastname: Park
authors.forename: Joon-Ho
authors.initials: JH
authors.lastname: Park
authors.forename: Eun-Young
authors.initials: EY
authors.lastname: Oh
authors.forename: Tae-Sik
authors.initials: TS
authors.lastname: Lim
authors.forename: Seongshim
authors.initials: S
authors.lastname: Cheong
authors.forename: In Hee
authors.initials: IH
authors.lastname: Cho
authors.forename: Jee Wook
authors.initials: JW
authors.lastname: Choi
mesh_terms: D000293:Adolescent; D001143:Arousal / Q000187:drug effects; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007175:Impulsive Behavior / Q000188:drug therapy; D007398:Interpersonal Relations; D007723:Korea; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D011597:Psychomotor Performance / Q000187:drug effects; D014705:Verbal Behavior / Q000187:drug effects
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate